123I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
123I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy. / Laursen, Adam Høgsbro; Thune, Jens Jakob; Hutchings, Martin; Hasbak, Philip; Kjaer, Andreas; Elming, Marie B; Ripa, Rasmus S.
I: Clinical Physiology and Functional Imaging, Bind 38, Nr. 2, 03.2018, s. 176-185.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - 123I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy
AU - Laursen, Adam Høgsbro
AU - Thune, Jens Jakob
AU - Hutchings, Martin
AU - Hasbak, Philip
AU - Kjaer, Andreas
AU - Elming, Marie B
AU - Ripa, Rasmus S
N1 - © 2017 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.
PY - 2018/3
Y1 - 2018/3
N2 - Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. (123) I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of (123) I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of (123) I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.
AB - Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. (123) I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of (123) I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of (123) I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.
KW - Journal Article
KW - Review
U2 - 10.1111/cpf.12419
DO - 10.1111/cpf.12419
M3 - Review
C2 - 28251781
VL - 38
SP - 176
EP - 185
JO - Clinical Physiology and Functional Imaging
JF - Clinical Physiology and Functional Imaging
SN - 1475-0961
IS - 2
ER -
ID: 174693568